Vision-Sciences Inc. (NASDAQ:CGNT) Director Kenneth A. Samet bought 25,000 shares of the firm’s stock in a transaction on Friday, November 18th. The stock was acquired at an average price of $2.47 per share, for a total transaction of $61,750.00. Following the completion of the purchase, the director now directly owns 125,000 shares in the company, valued at $308,750. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Vision-Sciences Inc. (NASDAQ:CGNT) traded up 4.3527% on Tuesday, reaching $2.3375. The company had a trading volume of 122,814 shares. The stock’s 50-day moving average is $1.77 and its 200-day moving average is $1.32. The company’s market capitalization is $141.19 million. Vision-Sciences Inc. has a 52 week low of $0.71 and a 52 week high of $2.53.

Several equities research analysts recently weighed in on CGNT shares. Zacks Investment Research upgraded Vision-Sciences from a “hold” rating to a “strong-buy” rating and set a $2.75 target price for the company in a report on Monday, November 14th. Roth Capital upgraded Vision-Sciences from a “neutral” rating to a “buy” rating in a report on Wednesday, September 7th.

Vision-Sciences Company Profile

Cogentix Medical, Inc, formerly Vision-Sciences, Inc, is a medical device company. The Company designs, develops, manufactures and markets products for endoscopy with its product lines featuring a visualization system and sterile disposable microbial barrier, EndoSheath technology. The Company produces and markets Endoscopes, such as cystoscopes, ureteroscopes, laryngoscopes, otoscopes, sinuscopes, trans-nasal esophagoscopy (TNE) and bronchoscopes for medical use and borescopes for industrial use, and digital processing units (DPU).

5 Day Chart for NASDAQ:CGNT

Receive News & Stock Ratings for Vision-Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vision-Sciences Inc. and related stocks with our FREE daily email newsletter.